Tian Zhang, MD, Duke Cancer Center
Articles by Tian Zhang, MD, Duke Cancer Center
Series Wrap-up: Novel Therapies for mRCC
BySumanta Kumar Pal, MD, City of Hope,Robert Alter, MD, John Theurer Cancer Center,David F. McDermott, MD, Dana Farber Harvard Cancer Center,Tian Zhang, MD, Duke Cancer Center,Bradley McGregor, MD, Dana-Farber Cancer Institute,Thomas E. Hutson, DO, PharmD, Texas Oncology A panel of expert oncologists who manage patients with renal cell carcinoma share enthusiasm over the use of newer novel-based treatment approaches for metastatic disease.
Second-Line Treatment Approaches for Metastatic RCC
BySumanta Kumar Pal, MD, City of Hope,Robert Alter, MD, John Theurer Cancer Center,David F. McDermott, MD, Dana Farber Harvard Cancer Center,Tian Zhang, MD, Duke Cancer Center,Bradley McGregor, MD, Dana-Farber Cancer Institute,Thomas E. Hutson, DO, PharmD, Texas Oncology A brief discussion on current second-line treatment options available to patients with metastatic renal cell carcinoma previously treated with a novel-based regimen.
Biomarker Development in mRCC
BySumanta Kumar Pal, MD, City of Hope,Robert Alter, MD, John Theurer Cancer Center,David F. McDermott, MD, Dana Farber Harvard Cancer Center,Tian Zhang, MD, Duke Cancer Center,Bradley McGregor, MD, Dana-Farber Cancer Institute,Thomas E. Hutson, DO, PharmD, Texas Oncology The significance of studying predictive biomarkers to help oncologists identify mechanisms of resistance to immunotherapy agents in metastatic renal cell carcinoma prior to initiating therapy.
mRCC Treatment: Novel-Based Approaches on the Horizon
BySumanta Kumar Pal, MD, City of Hope,Robert Alter, MD, John Theurer Cancer Center,David F. McDermott, MD, Dana Farber Harvard Cancer Center,Tian Zhang, MD, Duke Cancer Center,Bradley McGregor, MD, Dana-Farber Cancer Institute,Thomas E. Hutson, DO, PharmD, Texas Oncology An overview of novel-based treatment strategies and biomarkers that are currently under investigation to help address current unknowns when treating patients with metastatic renal cell carcinoma.
Frontline mRCC: I-O/TKI Treatment Regimens
BySumanta Kumar Pal, MD, City of Hope,Robert Alter, MD, John Theurer Cancer Center,David F. McDermott, MD, Dana Farber Harvard Cancer Center,Tian Zhang, MD, Duke Cancer Center,Bradley McGregor, MD, Dana-Farber Cancer Institute,Thomas E. Hutson, DO, PharmD, Texas Oncology Limitations of current data surrounding the appropriate use of immunotherapy plus a tyrosine kinase inhibitor as frontline therapy for patients with metastatic renal cell carcinoma and current recommendations for selecting an appropriate combination regimen.
Lenvatinib Plus Pembrolizumab or Everolimus for mRCC
BySumanta Kumar Pal, MD, City of Hope,Robert Alter, MD, John Theurer Cancer Center,David F. McDermott, MD, Dana Farber Harvard Cancer Center,Tian Zhang, MD, Duke Cancer Center,Bradley McGregor, MD, Dana-Farber Cancer Institute,Thomas E. Hutson, DO, PharmD, Texas Oncology Based on data demonstrated by the recent CLEAR study in metastatic renal cell carcinoma, oncologists comment on decisions for using lenvatinib plus pembrolizumab vs lenvatinib plus everolimus.
The CLEAR Study in mRCC
BySumanta Kumar Pal, MD, City of Hope,Robert Alter, MD, John Theurer Cancer Center,David F. McDermott, MD, Dana Farber Harvard Cancer Center,Tian Zhang, MD, Duke Cancer Center,Bradley McGregor, MD, Dana-Farber Cancer Institute,Thomas E. Hutson, DO, PharmD, Texas Oncology Robert S. Alter, MD, of the John Theurer Cancer Center, highlights key data revealed by the phase 3 CLEAR study in metastatic renal cell carcinoma.
PD-1 Vs PD-L1 Inhibition for Frontline mRCC
BySumanta Kumar Pal, MD, City of Hope,Robert Alter, MD, John Theurer Cancer Center,David F. McDermott, MD, Dana Farber Harvard Cancer Center,Tian Zhang, MD, Duke Cancer Center,Bradley McGregor, MD, Dana-Farber Cancer Institute,Thomas E. Hutson, DO, PharmD, Texas Oncology A panel of oncologists discuss the appropriateness for using PD-1 inhibitors versus PD-L1 inhibitors as frontline treatment for metastatic renal cell carcinoma.
Frontline Treatment for mRCC: Dose Adjustments/Discontinuation
BySumanta Kumar Pal, MD, City of Hope,Robert Alter, MD, John Theurer Cancer Center,David F. McDermott, MD, Dana Farber Harvard Cancer Center,Tian Zhang, MD, Duke Cancer Center,Bradley McGregor, MD, Dana-Farber Cancer Institute,Thomas E. Hutson, DO, PharmD, Texas Oncology Advice for appropriately dosing newer novel-based strategies used to treat metastatic renal cell carcinoma and best practices to help community oncologists avoid drug discontinuations.
Frontline Therapy for mRCC: Assessing Quality of Life
BySumanta Kumar Pal, MD, City of Hope,Robert Alter, MD, John Theurer Cancer Center,David F. McDermott, MD, Dana Farber Harvard Cancer Center,Tian Zhang, MD, Duke Cancer Center,Bradley McGregor, MD, Dana-Farber Cancer Institute,Thomas E. Hutson, DO, PharmD, Texas Oncology Expert oncologists debate the significance of using quality of life as a metric when assessing patients’ responses to therapy for metastatic renal cell carcinoma.
The CheckMate 9ER Study in mRCC
BySumanta Kumar Pal, MD, City of Hope,Robert Alter, MD, John Theurer Cancer Center,David F. McDermott, MD, Dana Farber Harvard Cancer Center,Tian Zhang, MD, Duke Cancer Center,Bradley McGregor, MD, Dana-Farber Cancer Institute,Thomas E. Hutson, DO, PharmD, Texas Oncology Takeaways of the CheckMate 9ER trial of nivolumab plus cabozantinib vs sunitinib in previously untreated metastatic renal cell carcinoma.
Novel Strategies for Intermediate-/Poor-Risk mRCC: Optimizing Therapy
BySumanta Kumar Pal, MD, City of Hope,Robert Alter, MD, John Theurer Cancer Center,David F. McDermott, MD, Dana Farber Harvard Cancer Center,Tian Zhang, MD, Duke Cancer Center,Bradley McGregor, MD, Dana-Farber Cancer Institute,Thomas E. Hutson, DO, PharmD, Texas Oncology Drs Bradley A. McGregor and David F. McDermott comment on best approaches for selecting and optimizing treatment with novel combination regimens to manage patients with intermediate- or poor-risk metastatic renal cell carcinoma.
Lenvatinib-Based Combinations for Intermediate-/Poor-Risk mRCC
BySumanta Kumar Pal, MD, City of Hope,Robert Alter, MD, John Theurer Cancer Center,David F. McDermott, MD, Dana Farber Harvard Cancer Center,Tian Zhang, MD, Duke Cancer Center,Bradley McGregor, MD, Dana-Farber Cancer Institute,Thomas E. Hutson, DO, PharmD, Texas Oncology Thomas E. Hutson, DO, PharmD, of Texas Oncology, reacts to results demonstrated by the CLEAR study of lenvatinib in combination with pembrolizumab or everolimus for the treatment of metastatic renal cell carcinoma and discusses best practices for educating community oncologists on dosing with lenvatinib.
Frontline Treatment for Intermediate/Poor-Risk mRCC
BySumanta Kumar Pal, MD, City of Hope,Robert Alter, MD, John Theurer Cancer Center,David F. McDermott, MD, Dana Farber Harvard Cancer Center,Tian Zhang, MD, Duke Cancer Center,Bradley McGregor, MD, Dana-Farber Cancer Institute,Thomas E. Hutson, DO, PharmD, Texas Oncology Considerations for evolving from using single-agent therapy to combination approaches to treat intermediate or poor-risk metastatic renal cell carcinoma based on more recent data demonstrated in clinical trials.
Favorable-Risk mRCC: Aggressive Therapy and Disease Progression
BySumanta Kumar Pal, MD, City of Hope,Robert Alter, MD, John Theurer Cancer Center,David F. McDermott, MD, Dana Farber Harvard Cancer Center,Tian Zhang, MD, Duke Cancer Center,Bradley McGregor, MD, Dana-Farber Cancer Institute,Thomas E. Hutson, DO, PharmD, Texas Oncology The rationale for treating favorable-risk metastatic renal cell carcinoma with early, aggressive therapy and considerations for approaching disease progression.
Favorable-Risk mRCC: First-Line Treatment Selection
BySumanta Kumar Pal, MD, City of Hope,Robert Alter, MD, John Theurer Cancer Center,David F. McDermott, MD, Dana Farber Harvard Cancer Center,Tian Zhang, MD, Duke Cancer Center,Bradley McGregor, MD, Dana-Farber Cancer Institute,Thomas E. Hutson, DO, PharmD, Texas Oncology Oncologists discuss how they select an appropriate novel combination strategy as first-line therapy for patients with favorable-risk metastatic renal cell carcinoma.
Favorable-Risk mRCC: Combination Regimens Vs Single-Agent Therapy
BySumanta Kumar Pal, MD, City of Hope,Robert Alter, MD, John Theurer Cancer Center,David F. McDermott, MD, Dana Farber Harvard Cancer Center,Tian Zhang, MD, Duke Cancer Center,Bradley McGregor, MD, Dana-Farber Cancer Institute,Thomas E. Hutson, DO, PharmD, Texas Oncology Factors that oncologists need to consider when deciding whether to initiate single-agent therapy or a novel combination regimen as frontline treatment for patients with favorable-risk metastatic renal cell carcinoma.
Favorable-Risk mRCC: Sequencing Therapy
BySumanta Kumar Pal, MD, City of Hope,Robert Alter, MD, John Theurer Cancer Center,David F. McDermott, MD, Dana Farber Harvard Cancer Center,Tian Zhang, MD, Duke Cancer Center,Bradley McGregor, MD, Dana-Farber Cancer Institute,Thomas E. Hutson, DO, PharmD, Texas Oncology Best approaches to sequencing therapy for patients with favorable-risk metastatic renal cell carcinoma following first-line therapy with novel combinations such as ipilimumab and nivolumab.
Frontline Treatment Approaches for Favorable-Risk mRCC
BySumanta Kumar Pal, MD, City of Hope,Robert Alter, MD, John Theurer Cancer Center,David F. McDermott, MD, Dana Farber Harvard Cancer Center,Bradley McGregor, MD, Dana-Farber Cancer Institute,Thomas E. Hutson, DO, PharmD, Texas Oncology,Tian Zhang, MD, Duke Cancer Center Current treatment approaches that can be used to treat favorable-risk metastatic renal cell carcinoma in the first-line setting and implications for individualizing therapy despite guidance provided by the IMDC criteria.
Treatment Advances for Frontline mRCC
BySumanta Kumar Pal, MD, City of Hope,Robert Alter, MD, John Theurer Cancer Center,David F. McDermott, MD, Dana Farber Harvard Cancer Center,Bradley McGregor, MD, Dana-Farber Cancer Institute,Thomas E. Hutson, DO, PharmD, Texas Oncology,Tian Zhang, MD, Duke Cancer Center Bradley A. McGregor, MD, of the Dana-Farber Cancer Institute, reacts to the emergence of new treatment gaps associated with novel combination regimens as first-line therapy for patients with metastatic renal cell carcinoma.
The CLEAR Study in mRCC
Frontline mRCC: I-O/TKI Treatment Regimens
Lenvatinib Plus Pembrolizumab or Everolimus for mRCC
Treatment Advances for Frontline mRCC
Frontline Treatment Approaches for Favorable-Risk mRCC
The CheckMate 9ER Study in mRCC